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INTRODUCTION
Diabetes mellitus, one of the most common endocrine-
metabolic disorders has caused significant morbidity and 
mortality due to micro vascular (retinopathy, neuropathy, 
and nephropathy) and macro vascular (heart attack, stroke, 
and peripheral vascular disease) complications (Patel et al., 
2011). This potential for multiple end organ damage 
from diabetes mellitus makes the proper control of blood 
sugar very critical during the management of diabetics 
(Blonde 2005). Currently, most individuals with chronic 
conditions such as diabetes, hypertension, and cancers in 
the developing countries prefer or rely on some form of 
traditional therapy. These treatments largely involve the 
use of herbal medicines alone or in combination with 
conventional treatments or care. The benefits of such 
therapies need to be assessed to ensure treatment goals 
are attained (Firenzuoli and Gori 2007).
In an earlier clinical study, we reviewed the fasting blood 
sugar (FBS) of patients treated with an infusion prepared 
from the coarsely powdered leaves of Bridelia ferrugenia 
[BRD]. It was established from this study that preparation 
caused a clinically insignificant decline in the FBS of patients 
using the herbal medicine. The results indicated a decline 
in FBS of 1.886 (confidence interval: 5.676-1.903) over 
a treatment period of 1 month (Thomford et al., 2015). 
Based on that report, a re-assessment of the product was 
undertaken to review the dosage used toward improving 
its efficacy and also ascertain the potential benefit of using 
the product in combination with metformin (MET) for 
individuals that may opt for such combinations.
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ABSTRACT
Herbal medicinal products play a significant role in the management of diabetes and other chronic diseases 
either as a monotherapy or in combination with allopathic treatments. The hypoglycemic activity of a Ghanaian 
herbal antidiabetic product (Bridelia Tea) prepared from the dried leaves of Bridelia ferrugenia [BRD] was re-
evaluated in this study with the view of improving, its activity and explore the possible benefit of using the 
product in combination with metformin (MET). Male and female Sprague-Dawley rats (210-220 g) were rendered 
hyperglycemic by a single intraperitoneal administration of streptozocin (70 mg/kg) after an overnight fast. The 
hyperglycemic rats then received one of the following treatments ([BRD 30 mg/kg or 300 mg/kg], [MET 250 mg/kg 
or 1000 mg/kg], [MET 250 mg/kg and BRD 30 mg/kg], [MET 1000 mg/kg and BRD 300 mg/kg]). The hypoglycemic 
effect of BRD, MET, and the combination of the two products were not significantly different during an initial 
6 h of monitoring (P > 0.05). In the long-term study over 28 days, BRD 300 mg/kg had hypoglycemic effects 
comparable to MET 1000 mg/kg p.o. and better than BDF 30 mg/kg p.o. (P < 0.05). However, the combination of 
the two products BRD and MET at the two doses reduced their therapeutic effect compared to animals receiving 
either one of the two treatments alone.
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METHODS
Plant Materials
The processed and packaged product prepared from the 
dried coarsely powdered plant material was obtained 
from the production unit of the Centre for Plant Medicine 
Research (CPMR).
Extraction
The plant materials were prepared according to the 
procedure listed out for patients using the product. 
A hot infusion was made by adding one tablespoon of the 
powdered leaves of BRD (≈ 6.49 g) in 500 ml of boiling 
water for 10-15 min and then decanting. The resultant 
extract had a dry weight of 0.97 g (± 0.20).
Animals Used and Handling
Adult male Sprague-Dawley rats aged between 3 and 
4 months and weighing 210-220 g were used for the study. 
They were housed under standard conditions at ambient 
temperature and supplied with standard pellets and 
water ad libitum at the animal house of the Department of 
Pharmacology, CPMR. All rats were handled in accordance 
with the accepted principles for laboratory animal use and 
care (EU directive of 1986:86/609/EEC).
Induction of Diabetes in Rats using Streptozotocin 
(STZ)
The bioassay employed was according to the description 
of Singh et al., (2001) with some modifications. STZ 
(0.588 g) was dissolved in freshly prepared 0.1 M citrate 
buffer solution of pH - 4.5. The blood glucose level of 
rats before the experiment were taken and found to be 
in the range of 3.9-4.7 mmol/l. The rats were injected 
intraperitoneally with a single dose of 70 mg STZ per kg 
body weight (BW) after an overnight fast. After injection, 
rats were given free access to food and water. After a 
rest period of 48 h, hyperglycemia was confirmed by 
determining the fasting blood glucose levels. The rats with 
blood glucose levels above 10.0 mmol/l, were selected 
for the experiment.
Test for Hypoglycemic Activities of BRD 
The diabetic rats were randomly divided into six groups 
of five animals each: Groups A - F. rats in groups A and B 
were given oral doses of 30 mg/kg and 300 mg/kg BRD 
p.o., respectively.  The 30 mg/kg dose of BRD is equivalent 
to the current prescribed dose for an adult diabetic 
patient. The rats in groups C and D received 250 mg/kg 
and 1000 mg/kg of the standard antidiabetic drug MET. 
Group E received the combination of 30 mg/kg BRD and 
250 mg/kg of MET. Animals in Groups F were also treated 
with both 300 mg/kg BRD and 1000 mg/kg MET.
Statistical Analysis
All data provided in this study represent mean ± 
standard error mean. The results were analyzed using 
a one and two-way Analysis of Variance followed by 
Bonferronni’s post-test. Results were considered 
significant if P < 0.05.
RESULTS
The Hypoglycemic Activity of BRD  and its 
Combination with MET
In the 6 hr glucose control monitoring for the various 
groups, the decline in FBS was not significantly different 
across the groups (Figure 1). Animals treated with 
30 mg/kg BRD recorded a 36.13% (8.02 ± 1.28 mmol/l) 
decline in their mean FBS over the 6 hr period.  The group 
treated with 300 mg/kg of the BRD also had a 30.32% 
(6.62 ± 1.38 mmol/l) reduction in mean FBS.
The standard antidiabetic treatment MET resulted in 
33.30% (7.36 ± 1.51) and a 47.24% (9.28 ± 3.09 mmol/l) 
decline in mean FBS for animals treated with 250 mg/kg 
and 1000 mg/kg, respectively.  The combined treatment of 
MET and BRD also caused a 34.02% (7.26 ± 1.02 mmol/l) 
decline in mean FBS for animals receiving 30 mg/kg BRD 
and 250 mg/kg MET.  The rats treated with 300 mg/kg BRD 
and 1000 mg/kg MET had a 26.17% (4.68 ± 1.18 mmol) 
reduction in their FBS.
The activity observed during the 28-day study indicated 
that BRD (300 mg/kg p.o.; FBS: 3.65 ± 0.14 mmol/l) 
had better hypoglycemic effects than BRD (30 mg/kg p.o.; 
FBS: 5.47 ± 1.21 mmol/l) with P < 0.05 and comparable 
activity to MET (1000 mg/kg p.o.; 2.90 ± 0.06 mmol/l) 
at the end of the study (Figure 2).
The combination of the two treatments: BRD and MET 
(30 mg/kg p.o. and 250 mg/kg p.o., respectively) 
however was lower in therapeutic effect (FBS: 20.0 ± 
0.56 mmol/l) when compared to animals receiving 
only BRD 30 mg/kg p.o. (FBS: 5.47 ± 1.21 mmol/l; 
***P < 0.001) but not significantly different from animals 
treated with only MET 250 mg/kg p.o. (FBS: 17.15 ± 
2.15 mmol/l; P > 0.05). Similar effects were recorded 
for the combination of BRD and MET (300 mg/kg p.o. 
and 1000 mg/kg p.o., respectively; FBS of 17.88 ± 
1.02 mmol/l) compared to rats treated with only BRD 
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300 mg/kg p.o. (FBS: 3.65 ± 0.14 mmol/l; ***P < 0.001) 
and those receiving only MET 1000 mg/kg p.o. (2.90 ± 
0.06 mmol/l; ***P < 0.001).
Effect of Treatments on the BW of Diabetic Rat
The BW of animals taken at the baseline (day 0), mid-study 
(day 14), and the end-of-study (day 28) is reported as 
Table 1. The normal control recorded a 4.27% increment 
in their weight. The diabetic controls recorded a 31.64% 
decline in their BW. Animals receiving BRD 30 mg/kg 
also had an 11.08% decline with BRD 300 mg/kg having 
a 9.68% reduction. BW also declined by 10.78% for 
rats treated with MET 500 mg/kg, 9.54% for MET 
1000 mg/kg, 7.44% for MET + BRD (30 + 500 mg/kg), 
and 9.27% for MET + BRD (300 + 1000 mg/kg).
DISCUSSION
Although BRD had been reported as having antidiabetic 
properties by some authors (Iwu 1983; Njamen et al., 
2012), our previous clinical study indicated otherwise 
(Thomford et al., 2015). However, the possibility of the 
dosage, dosage form, and standardization affecting the 
overall efficacy of the product meant this in vivo study 
had to be undertaken to review the dose of the product; 
a critical factor affecting the biological effect of botanical 
treatments (Ahmad et al., 2006).
The current dosage administered to patient visiting the 
clinic of the CPMR was calculated to be approximately 
30 mg/kg representing the minimum dose accessed during 
Figure 2: Effect of treatments on the mean fasting blood sugar of rats receiving Bridelia ferrugenia (BRD) (30 mg/kg p.o.; Group A), 
BRD (300 mg/kg p.o.; Group B), metformin (MET) (250 mg/kg p.o; Group C), MET (1000 mg/kg p.o.; Group D), MET + BRD (250 mg/kg and 
30 mg/kg p.o; Group E), and MET + BRD (1000 mg/kg and 300 mg/kg p.o.; Group F) shown on the time course curve (a) and the histogram 
(b) during the 28 days of follow up. Data is represented as mean ± standard error mean, n = 5. *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
BRD (30 mg/kg p.o.). †P ≤ 0.05, ††P ≤ 0.01, †††P ≤ 0.001 compared BRD (30 mg/kg) followed by Bonferonni’s posttest
ba
Figure 1: Effect of treatments on the mean fasting blood sugar of rats receiving Bridelia ferrugenia (BRD) (30 mg/kg p.o.; Group A) 
BRD (300 mg/kg p.o.; Group B), metformin (MET) (250 mg/kg p.o; Group C), MET (1000 mg/kg p.o.; Group D), MET + BRD (250 mg/kg and 
30 mg/kg p.o; Group E), and MET + BRD (1000 mg/kg and 300 mg/kg p.o.; Group F) shown on the time course curve (a) and the histogram 
(b) during the 6 h of glucose monitoring. Data is represented as mean ± standard error mean, n = 5, One and two-way ANOVA compared to BRD 
(30 mg/kg p.o.) followed by Bonferroni’s posttest
ba
 Thomford, et al.: Antidiabetic activity of Bridelia ferrugenia
78 Journal of Medicinal Herbs and Ethnomedicine ● Vol 1 ● Issue 1 ●  2015
this experiment. The hypoglycemic effect of the 2 doses 
of BRD were significantly different after 28 days (BRD 
30 mg/kg p.o. [5.47 ± 1.22 mmol/l] and BRD 300 mg/kg 
p.o. [3.65 ± 0.14 mmol/l]; P < 0.05). The response 
obtained for the highest dose of BRD was also comparable 
to animals that received MET only (1000 mg/kg p.o.). 
These findings indicate that the hypoglycemic effect of 
the plant may be improved with an increase in the dosage 
currently administered.
Significantly, the combination of MET and BRD also 
decreased the therapeutic response obtained during this 
study implying a possible herb-drug interaction. Some 
herbal products have been noted to have such interactions 
with their biological activity noted to affect either the 
bioavailability, metabolism and/or clearance of allopathic 
drugs. In some instances, these interactions have been 
exploited for the benefit of patients as in the case of the 
administration of Senna and the opioid analgesics during 
palliative care. Other interactions such as the combined 
use of St. John’s Worts and Warfarin have been reported 
as potentially dangerous (Agra et al., 1998; McEwen, 
2015). Therefore, the negative interaction between BRD 
and MET, needs to be explored further.
Finally, reformulation of the product from its current 
dosage form of a powder may have to be considered if 
the increase in dosage is to be implemented especially to 
ensure patient compliance.
CONCLUSION
The study has shown that clinical activity of the product 
may be improved by an increase in the dosage from the 
current 30 mg/kg to 300 mg/kg. It is also relevant to 
further study the nature of the herb-drug interaction 
between BRD and MET.
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Table 1: Effect of treatments on the body weight of diabetic rat 
during the study
Treatment group Day 0 Day 14 Day 28
Normal control 215.49±2.31 227.87±1.51 225.10±3.29
Diabetic control 212.30±1.05 177.19±4.31 145.12±5.37
BRD 30 mg/kg 217.79±0.98 193.66±2.11 183.76±1.98
BRD 300 mg/kg 214.18±1.33 198.32±1.97 193.45±2.37
MET 500 mg/kg 215.31±0.96 197.51±2.07 192.11±3.57
MET 1000 mg/kg 219.74±2.83 199.32±3.11 195.13±4.31
BRD+
MET (30+500) mg/kg
214.39±0.64 201.31±0.91 198.45±4.50
BRD+
MET (300+1000) mg/kg
217.59±3.01 203.86±1.91 197.41±1.07
Data is represented as mean±SEM, n=5. Body weights of the diabetic 
control and the treatment groups with significantly different (P<0.001) 
compared to the normal control on day 14 and 28, SEM: Standard error 
mean, BRD: Bridelia ferrugenia, MET: Metformin
